Biomarkers for non-human primate Type-I hypersensitivity: Antigen-specific immunoglobulin E assays

Journal of Immunological Methods

Volumn 392, Issue 1-2, 2013, Pages 29-37

  Clark, Darcey ^a   Shiota, Faith ^a   Forte, Carla ^a   Narayanan, Padma ^a   Mytych, Daniel T ^a   Hock, M Benjamin ^a  

^a AMGEN INC   (United States)

Author keywords

Anti drug antibody; Hypersensitivity; IgE; Immunogenicity; Non human primate

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN E ANTIBODY;

ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; BIOASSAY; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; CROSS REACTION; HISTAMINE RELEASE; HYPERSENSITIVITY; IMMUNOGENICITY; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; TYPE 1 HYPERSENSITIVITY; ANIMAL CELL CULTURE; ANTIBODY SCREENING; CELL ACTIVATION; EMBRYO; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; MACACA FASCICULARIS; PATHOPHYSIOLOGY; PRIMATE MODEL; TOXICOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD34; BIOLOGICAL MARKERS; CROSS REACTIONS; EPITOPES; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, IMMEDIATE; IMMUNOASSAY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MAST CELLS; MOLECULAR SEQUENCE DATA; RECEPTORS, IGE;

ANIMALIA; MACACA FASCICULARIS; PRIMATES;

EID: 84880045370     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.03.007     Document Type: Article

References (36)

1. Bautista A.C., Salimi-Moosavi H., Jawa V. Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure. AAPS J. 2012, 14:843.
2. Benhamou A.H., Zamora S.A., Eigenmann P.A. Correlation between specific immunoglobulin E levels and the severity of reactions in egg allergic patients. Pediatr. Allergy Immunol. 2008, 19:173.
3. Caughey G.H. Mast cell tryptases and chymases in inflammation and host defense. Immunol. Rev. 2007, 217:141.
4. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., Slebos R.J., Zhou Q., Gold D., Hatley T., Hicklin D.J., Platts-Mills T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 358:1109.
5. Del Prete G., Maggi E., Parronchi P., Chretien I., Tiri A., Macchia D., Ricci M., Banchereau J., De Vries J., Romagnani S. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J. Immunol. 1988, 140:4193.
6. European Medicines Agency Committee for Medicinal Products for Human Use Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins 2007.
7. European Medicines Agency Committee for Medicinal Products for Human Use Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use 2012.
8. Finkelman F.D., Katona I.M., Urban J.F., Holmes J., Ohara J., Tung A.S., Sample J.V., Paul W.E. IL-4 is required to generate and sustain in vivo IgE responses. J. Immunol. 1988, 141:2335.
9. Flaherty M.M., MacLachlan T.K., Troutt M., Magee T., Tuaillon N., Johnson S., Stein K.E., Bonvini E., Garman R., Andrews L. Nonclinical evaluation of GMA161 - an antihuman CD16 (FcgammaRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol. Sci. 2012, 125:299.
10. Food and Drug Administration (FDA) DRAFT- Guidance for Industry, Assay Development for Immunogenicity Testing of Therapeutic Proteins 2009.
11. Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat. Rev. Immunol. 2008, 8:205.
12. Hamilton R.G., Adkinson F., Baltrukonis D., Cullen C., Emrich T., Geng D., Halsey J.F., Homburger H.A., Hovanec-Burns D.L., Kirshner S.L., Matsson P., Moxness M., Xu Y. Design and validation of immunoassays for assessment of human allergenicity of new biotherapeutic drugs; approved guideline 2011, vol. 31. Clinical and Laboratory Standards Institute.
13. Holdom M.D., Davies A.M., Nettleship J.E., Bagby S.C., Dhaliwal B., Girardi E., Hunt J., Gould H.J., Beavil A.J., McDonnell J.M., Owens R.J., Sutton B.J. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcvarepsilonRI. Nat. Struct. Mol. Biol. 2011, 18:571.
14. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 2005, 115:459.
15. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) ICH harmonised tripartite guideline: preclinical safety evaluation of biotechnology derived biopharmeceuticals 2011, (S6(R1)).
16. Ishizaka K., Ishizaka T., Hornbrook M.M. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol. 1966, 97:75.
17. Jacobsen F.W., Padaki R., Morris A.E., Aldrich T.L., Armitage R.J., Allen M.J., Lavallee J.C., Arora T. Molecular and functional characterization of cynomolgus monkey IgG subclasses. J. Immunol. 2011, 186:341.
18. Jonsson F., Mancardi D.A., Kita Y., Karasuyama H., Iannascoli B., Van Rooijen N., Shimizu T., Daeron M., Bruhns P. Mouse and human neutrophils induce anaphylaxis. J. Clin. Invest. 2011, 121:1484.
19. Jonsson F., Mancardi D.A., Zhao W., Kita Y., Iannascoli B., Khun H., van Rooijen N., Shimizu T., Schwartz L.B., Daeron M., Bruhns P. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 2012, 119:2533.
20. Khodoun M.V., Strait R., Armstrong L., Yanase N., Finkelman F.D. Identification of markers that distinguish IgE- from IgG-mediated anaphylaxis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12413.
21. Lappalainen J., Lindstedt K.A., Kovanen P.T. A protocol for generating high numbers of mature and functional human mast cells from peripheral blood. Clin. Exp. Allergy 2007, 37:1404.
22. Meng Y.G., Singh N., Wong W.L. Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor. Mol. Immunol. 1996, 33:635.
23. Palm N.W., Rosenstein R.K., Medzhitov R. Allergic host defences. Nature 2012, 484:465.
24. Patelis A., Gunnbjornsdottir M., Malinovschi A., Matsson P., Onell A., Hogman M., Alving K., Janson C. Population-based study of multiplexed IgE sensitization in relation to asthma, exhaled nitric oxide, and bronchial responsiveness. J. Allergy Clin. Immunol. 2012, 130:397.
25. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat. Rev. Immunol. 2010, 10:225.
26. TM therapeutic. Society of Toxicology Annual Meeting, San Francisco, CA 2012.
27. Rolinck-Werninghaus C., Keil T., Kopp M., Zielen S., Schauer U., von Berg A., Wahn U., Hamelmann E. Specific IgE serum concentration is associated with symptom severity in children with seasonal allergic rhinitis. Allergy 2008, 63:1339.
28. Steenholdt C., Svenson M., Bendtzen K., Thomsen O.O., Brynskov J., Ainsworth M.A. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2011, 34:51.
29. Steenholdt C., Svenson M., Bendtzen K., Thomsen O.O., Brynskov J., Ainsworth M.A. Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease. J. Crohn's Colitis 2012, 6:108.
30. Strait R.T., Morris S.C., Finkelman F.D. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J. Clin. Invest. 2006, 116:833.
31. Stubenrauch K., Wessels U., Essig U., Vogel R., Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 2010, 52:249.
32. Swanson S.J., Bussiere J. Immunogenicity assessment in non-clinical studies. Curr. Opin. Microbiol. 2012, 15:337.
33. Trivedi N.N., Raymond W.W., Caughey G.H. Chimerism, point mutation, and truncation dramatically transformed mast cell delta-tryptases during primate evolution. J. Allergy Clin. Immunol. 2008, 121:1262.
34. Vultaggio A., Matucci A., Nencini F., Pratesi S., Parronchi P., Rossi O., Romagnani S., Maggi E. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010, 65:657.
35. Yoshimoto T., Yasuda K., Tanaka H., Nakahira M., Imai Y., Fujimori Y., Nakanishi K. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat. Immunol. 2009, 10:706.
36. Zetterstrom O., Johansson S.G. IgE concentrations measured by PRIST in serum of healthy adults and in patients with respiratory allergy. A diagnostic approach. Allergy 1981, 36:537.